In HER2 positive breast cancer, the presence of HER2, a tyrosine kinase receptor that is part of the EGFR family, enables targeted therapeutics (Trastuzumab, Pertuzumab) to be effective [9, 10]. Here, ERBB2 is linked to breast cancer.